Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of PURETHAL Grasses Rush Induction in Allergic Rhinoconjunctivitis
NCT01059266Phase 4Completed
- Sponsor
- HAL Allergy Group
- Start
- Feb 2010
- Primary completion
- Sep 2010
- Modality
- Recombinant Proteins and Enzymes, Therapeutic Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Purethal in allergic rhinoconjunctivitis (ARC), sponsored by HAL Allergy Group. Started Feb 2010; status: completed.
02
Drugs
Purethal
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NCT01059266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059266.